Tigermed Profit Soars 119% to RMB 888M, Slashes Dividend

Edgen Stock

·Mar 30 2026, 09:18

Share to

Share to

Copy link

Key Takeaways

Chinese contract research organization Tigermed reported a massive jump in profitability for its 2025 fiscal year, even as revenue growth slowed. However, the company significantly reduced its dividend payout to shareholders, signaling a potential shift in its capital allocation strategy.

Massive Profit Growth: Net profit for the year ending in December surged 119.2% to RMB 888 million.
Slowing Revenue: Top-line growth moderated, with revenue increasing by only 3.5% year-over-year to RMB 6.833 billion.
Dividend Cut: The company declared a final dividend of RMB 0.126, a steep drop from the prior year's RMB 0.3000 payout.

Net Profit Jumps 119.2% on Slowing Revenue

Tigermed (3347.HK) announced a substantial increase in profitability for its full fiscal year ending in December 2025, with net profit reaching RMB 888 million. This figure marks a 119.2% increase compared to the previous year. The dramatic profit expansion occurred despite a slowdown in top-line growth, as annual revenue climbed a modest 3.5% to RMB 6.833 billion. The company's earnings per share for the period stood at RMB 1.04.

In a move contrasting with its strong bottom-line performance, Tigermed's board declared a final dividend of RMB 0.126 per share. This represents a significant reduction from the final dividend of RMB 0.3000 distributed in the prior year. The decision to lower the shareholder payout, even with soaring profits, suggests a strategic shift towards retaining capital, possibly for future investments or to bolster its balance sheet.

Net Profit Jumps 119.2% on Slowing Revenue

Final Dividend Cut to RMB 0.126 Per Share